LGALS9 and head and neck squamous cell carcinoma: Due to the clinical relevance of PD-14, TIM-340, and LAG3-targeting41 therapies currently being used or tested, we validated the PD-L1, galectin-9, and HLA-DR expression at the protein level and corroborated that myeloid population are the major contributors to the ICL expression in the HNSCC TME.